High concentration local anesthetic formulations
A transdermal topical anesthetic formulation, which can be used to ameliorate or inhibit pain, has been developed. In the preferred embodiment, the topical anesthetic is a local anesthetic such as lidocaine, most preferably lidocaine free-base in a gel, and the dosage of the local anesthetic is effective in the painful area or immediately adjacent areas, to ameliorate or eliminate the pain. High concentration of local anesthetic in solution in the carrier is used to drive rapid release and uptake of the drug. Relief is typically obtained for a period of several hours.
1. A method of treating pain, comprising
topically administering an effective amount of a formulation to a site in need thereof to treat the pain, wherein the formulation comprises a free base caine alkaloid local anesthetic in an amount of about 40% by weight of the formulation,
the formulation is a non-aqueous gel,
the free base caine alkaloid local anesthetic is lidocaine free base, and
the free base caine alkaloid local anesthetic is released into the skin for at least three hours to provide pain relief at or near the site of administration without systemic toxicity.
2. The method of claim 1 providing an initial burst release within two hours of administration.
3. The method of claim 1 providing an initial burst release within four hours of administration.
4. The method of claim 1 providing an initial burst release within six hours of administration.
5. The method of claim 1 providing an initial burst release within eight hours of administration.
6. The method of claim 1 providing an initial burst release within twelve hours of administration.
7. The method of claim 1 for administration to wounds, abrasions, or burns.
8. The method of claim 1 , wherein the local anesthetic is lidocaine free base in a gel comprising propylene glycol, dehydrated alcohol, isopropyl myristate, diethylene glycol monoethyl ether, and hydroxypropylcellulose.
9. The method of claim 8 , wherein the concentration of propylene glycol is from about 1% to about 20% w/w, the concentration of dehydrated alcohol is about 18.80% w/w, the concentration of isopropyl myristate is about 10% w/w, the concentration of diethylene glycol monoethyl ether is about 10% w/w and hydroxypropyl cellulose is about 1.2%.
10. The method of claim 9 , wherein the local anesthetic is lidocaine free base in a gel comprising about 20% w/w propylene glycol.
11. The method of claim 10 , wherein the local anesthetic is lidocaine free base in a gel comprising 20% w/w propylene glycol, 18.80% w/w dehydrated alcohol, 10% w/w isopropyl myristate, 10% w/w diethylene glycol monoethyl ether and 1.2% w/w hydroxypropylcellulose.
12. The method of claim 1 wherein the free base caine alkaloid local anesthetic is present in an amount of 40% by weight of the formulation.
13. The method of claim 1 wherein the formulation comprises diglycol monoethyl ether and propylene glycol.
14. The method of claim 13 wherein the formulation comprises ethanol and hydroxypropyl cellulose.
15. The method of claim 14 wherein the formulation comprises isopropyl myristate.
16. The method of claim 14 wherein the formulation comprises dimethyl isosorbide.
17. The method of claim 1 wherein the formulation is a gel containing 40% w/w lidocaine free base, 20% w/w diglycol monoethyl ether, 10% w/w propylene glycol, 10% w/w dimethyl isosorbide, 18.80% w/w ethanol, and 1.2% w/w hydroxypropyl cellulose.
18. The method of claim 1 wherein the formulation is a gel containing 40% w/w lidocaine free base, 10% w/w isopropyl myristate, 10% w/w diglycol monoethyl ether, 20% w/w propylene glycol, 18.80% w/w ethanol, and 1.2% w/w hydroxypropyl cellulose.
19. The method of claim 1 , wherein the pain is neuropathic pain.
20. The method of claim 17 , wherein the pain is neuropathic pain.
21. The method of claim 18 , wherein the pain is neuropathic pain.
22. The method of claim 14 , wherein the pain is neuropathic pain.
23. The method of claim 15 , wherein the pain is neuropathic pain.
24. The method of claim 16 , wherein the pain is neuropathic pain.
25. The method of claim 19 , wherein the method comprises topically administering the formulation to a wound.
26. The method of claim 20 , wherein the method comprises topically administering the formulation to a wound.
27. The method of claim 21 , wherein the method comprises topically administering the formulation to a wound.
28. The method of claim 22 , wherein the method comprises topically administering the formulation to a wound.
29. The method of claim 23 , wherein the method comprises topically administering the formulation to a wound.
30. The method of claim 1 , wherein the pain is non-neuropathic pain.
31. The method of claim 15 , wherein the pain is non-neuropathic pain.
32. The method of claim 16 , wherein the pain is non-neuropathic pain.